| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C14H9NO5S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. It enhanced the inhibitory effect of Cisplatin and Paclitaxel on ovarian cancer cell formation, migration, and growth[1]. It is supplied as a light yellow to yellow solid (C14H9NO5S, MW 303.29) at 99.45% purity.
Physical & Chemical Properties
| CAS Number | 1260247-42-4 |
|---|---|
| Molecular Formula | C14H9NO5S |
| Molecular Weight | 303.29 g/mol |
| Purity | 99.45% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | O=S(C(C=CC=C1C(C2=C3C=CC=C2O)=O)=C1C3=O)(N)=O |
| Target | p-STAT3 |
| Signaling Pathway | JAK/STAT Signaling; Stem Cell/Wnt |
| Solubility | In Vitro: DMSO: 100 mg/mL (329.72 mM; Requires sonication and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, protect from light. In solvent: -80°C, 6 months; -20°C, 1 month (protect from light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (329.72 mM) | requires sonication and warming and heat to 60°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); protect from light; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 2% DMSO + 40% PEG300 + 5% Tween-80 + 53% saline |
|---|---|
| Result | 0.5 mg/mL (1.65 mM); suspension; requires sonication |
Data provided by the manufacturer.
In Vitro
LLL12 (0.01-1 μM; 72 h) lowers the viability of ovarian cancer cell lines, in the presence or absence of Cisplatin (0.5 μM, 2.5 μM) together with Paclitaxel (0.25 μM, 0.5 μM)[1]. LLL12 (0.25-1.0 μM; 72 h) suppresses STAT3 phosphorylation (Tyr705) in ovarian cancer cell lines[1].
Western Blot Analysis[1]
| Cell Line | A2780, SKOV3, CAOV-3 and OVCAR5 ovarian cancer cell lines |
|---|---|
| Concentration | 0.25, 0.5, and 1 μM for A2780 and OVCAR5; 1, 2.5, and 5 μM for SKOV3 and CAOV-3 |
| Incubation Time | 72 hours |
| Result | Inhibited STAT3 phosphorylation at Tyr705. |
In Vivo
LLL12 (5 mg/kg; i.p.; once daily for 13 d) exerts strong growth-inhibitory activity against mouse osteosarcoma cells and tumor growth[2].
| Animal Model | Mouse xenografts with SJSA or OS-33 osteosarcoma cells[2] |
|---|---|
| Dosage | 5 mg/kg |
| Administration | Intraperitoneal injection; once daily for 13 days |
| Result | Resulted in a significant reduction in tumor volume and tumor mass in the OS-33 and SJSA xenografted mice. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. Cell Rep Med 2026 Jun 16;7(6):102833. PMID: 42173096
Puerarin mitigates cognitive decline and white matter injury via CD36-Mediated microglial phagocytosis in chronic cerebral hypoperfusion. Phytomedicine 2025 Mar:138:156396. PMID: 39827816
